STUDIES IN THYROID DISEASE

两种形式的辅助治疗旨在提高 碘-131辐射在甲状腺癌中的研究正在进行中。第一种是锂 离子，用于延长I-131在癌症中的滞留时间。 初步调查结果已在以前的年度报告中进行了描述。这个 二是使用阿霉素(阿霉素)作为放射增敏剂。 为了评估其有效性，我们已经开始了一项随机研究， 接受标准I-131治疗的高危甲状腺癌患者 或不注射小剂量阿霉素(10 mg/平方米)30分钟 在每个I-131治疗剂量之前。据我们所知，这是第一次 甲状腺癌治疗方案中患者随机化的尝试 使用I-131。 其他I-131阴性但升高的全身扫描患者 甲状旁腺素治疗后血中甲状腺球蛋白浓度的变化 尝试通过治疗后扫描来定位癌症。大多数患者都有 被发现在治疗后扫描呈阳性，他们正在接受 评估该疗法可能的有益效果。

Two forms of adjuvant therapy designed to improve the effectiveness of I-131 radiation in thyroid cancer are under study. The first is lithium ion, which is used to prolong the retention of I-131 in the cancer. Preliminary findings have been described in previous annual reports. The second is the use of doxorubicin (adriamycin) as a radiosensitizing agent. To evaluate its effectiveness, we have begun a randomized study of high-risk thyroid cancer patients who receive standard I-131 therapy with or without the administration of low-dose adriamycin (10mg/square m) 30 min preceding each I-131 treatment dose. To our knowledge, this is the first attempt to randomize patients in a therapy protocol for thyroid cancer employing I-131. Other patients with negative I-131 whole body scans but elevated concentration of thyroglobulin in blood are given I-131 therapy in an attempt to localize the cancer by post-therapy scanning. Most patients have been found to have positive post-therapy scans and they are under evaluation for possible beneficial effects of the therapy.